Up to 76% of Alzheimer’s patients experience agitation1. IGC-AD1, currently enrolling in a Phase 2 trial, brings hope as a treatment for agitation in Alzheimer’s.
What is Agitation in Alzheimer's?
Welcome to CALMA, a multicenter Phase 2 clinical trial designed to evaluate the safety and efficacy of IGC-AD1 for treating agitation associated with Alzheimer’s dementia.
Diagnosis of Alzheimer’s Disease.
Symptoms of agitation, aggression, irritability, or restlessness.
Regular behavioral medications are permitted before and during the study.
Have a caregiver who maintains daily contact with the study participant and commits to complying with the study procedures.
- Assess the efficacy of IGC-AD1 on cognition at Week 6.
- Measure changes in caregiver burden.
- Safety and Tolerability
- Analyze the biomarker panel.
- Daily Logbook with vitals.
In Clinic Visits
Day 0, Week 2, Week 4, and Week 6
Safety Calls
Daily for the first three days, and every third day thereafter to review safety and compliance.
Plan Your Visit
We invite you to participate in our clinical trial, with locations conveniently available across the US and Canada. Use the map below to find the site nearest to you.
- Jones, E., Aigbogun, M. S., Pike, J., Berry, M., Houle, C. R., & Husbands, J. (2021). Agitation in Dementia: Real-World Impact and Burden on Patients and the Healthcare System. Journal of Alzheimer’s disease : JAD, 83(1), 89–101. https://doi.org/10.3233/JAD-210105
